Hepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCV | Zendy

Eishiro Mizukoshi | Zendy; Christoph Eisenbach | Zendy; Brian R. Edlin | Zendy; Kimberly P. Newton | Zendy; Sukanya Raghuraman | Zendy; Christina WeilerNormann | Zendy; Leslie H. Tobler | Zendy; Michael P. Busch | Zendy; Mary Carrington | Zendy; Jane A. McKeating | Zendy; Thomas R. OʼBrien | Zendy; Barbara Rehermann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCV

Author(s) -

Eishiro Mizukoshi,

Christoph Eisenbach,

Brian R. Edlin,

Kimberly P. Newton,

Sukanya Raghuraman,

Christina WeilerNormann,

Leslie H. Tobler,

Michael P. Busch,

Mary Carrington,

Jane A. McKeating,

Thomas R. OʼBrien,

Barbara Rehermann

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/589510

Subject(s) - elispot , hepatitis c virus , immunology , medicine , virology , antibody , hepatitis c , hepacivirus , immune system , virus , t cell

Injection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research